Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Increase (Decrease) in Accounts Payable and Accrued Liabilities

2.8 / 5 stars · 68/120 Roast Me

CYPHERPUNK TECHNOLOGIES INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities

CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$2.46 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12

  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$881.00K, a 190.92% decline year-over-year.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.57M.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$4.75M.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was -$6.27M.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was -$10.42M, a 1255.32% decline from fiscal 2024.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $902.00K, a 26.69% increase from fiscal 2023.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $712.00K, a 24.66% decline from fiscal 2022.
  • CYPHERPUNK TECHNOLOGIES INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $945.00K, a 75.77% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Payable and Accrued Liabilities 3 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 6 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 9 monthIncrease (Decrease) in Accounts Payable and Accrued Liabilities 12 month
2026-06-30-$881.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$2.46M
10-Q · filed 2026-08-12
-$7.21M
derived: sum of 3 quarters · filed 2026-08-12
-$13.47M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$1.57M
10-Q · filed 2026-05-14
-$6.32M
derived: sum of 2 quarters · filed 2026-05-14
-$12.59M
derived: sum of 3 quarters · filed 2026-05-14
-$11.62M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$4.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$11.02M
derived: sum of 2 quarters · filed 2026-03-16
-$10.05M
derived: sum of 3 quarters · filed 2026-08-12
-$10.42M
10-K · filed 2026-03-16
2025-09-30-$6.27M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
-$5.30M
derived: sum of 2 quarters · filed 2026-08-12
-$5.67M
10-Q · filed 2025-11-12
-$7.34M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$969.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
$596.00K
10-Q · filed 2026-08-12
-$1.07M
derived: sum of 3 quarters · filed 2026-08-12
-$1.19M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$373.00K
10-Q · filed 2026-05-14
-$2.04M
derived: sum of 2 quarters · filed 2026-05-14
-$2.16M
derived: sum of 3 quarters · filed 2026-05-14
$2.92M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$1.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16
-$1.78M
derived: sum of 2 quarters · filed 2026-03-16
$3.29M
derived: sum of 3 quarters · filed 2026-03-16
$902.00K
10-K · filed 2026-03-16
2024-09-30-$114.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12
$4.96M
derived: sum of 2 quarters · filed 2025-11-12
$2.57M
10-Q · filed 2025-11-12
$4.29M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30$5.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14
$2.69M
10-Q · filed 2025-08-14
$4.41M
derived: sum of 3 quarters · filed 2025-08-14
$3.78M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$2.39M
10-Q · filed 2025-05-13
-$668.00K
derived: sum of 2 quarters · filed 2025-05-13
-$1.29M
derived: sum of 3 quarters · filed 2025-05-13
$522.00K
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$1.72M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26
$1.09M
derived: sum of 2 quarters · filed 2025-03-26
$2.91M
derived: sum of 3 quarters · filed 2025-03-26
$712.00K
10-K · filed 2025-03-26
2023-09-30-$624.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$1.19M
derived: sum of 2 quarters · filed 2024-11-13
-$1.01M
10-Q · filed 2024-11-13
-$2.23M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$1.81M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12
-$382.00K
10-Q · filed 2024-08-12
-$1.60M
derived: sum of 3 quarters · filed 2024-08-12
-$116.00K
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$2.20M
10-Q · filed 2024-05-13
-$3.42M
derived: sum of 2 quarters · filed 2024-05-13
-$1.93M
derived: sum of 3 quarters · filed 2024-05-13
$1.12M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$1.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
$266.00K
derived: sum of 2 quarters · filed 2024-03-18
$3.31M
derived: sum of 3 quarters · filed 2024-03-18
$945.00K
10-K · filed 2024-03-18
2022-09-30$1.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
$4.54M
derived: sum of 2 quarters · filed 2023-11-13
$2.17M
10-Q · filed 2023-11-13
$1.19M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$3.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$679.00K
10-Q · filed 2023-08-14
-$294.00K
derived: sum of 3 quarters · filed 2023-08-14
$3.09M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$2.37M
10-Q · filed 2023-05-15
-$3.34M
derived: sum of 2 quarters · filed 2023-05-15
$44.00K
derived: sum of 3 quarters · filed 2023-05-15
$1.15M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$973.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24
$2.41M
derived: sum of 2 quarters · filed 2023-03-24
$3.51M
derived: sum of 3 quarters · filed 2023-03-24
$3.90M
10-K · filed 2023-03-24
2021-09-30$3.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$4.49M
derived: sum of 2 quarters · filed 2022-11-14
$4.87M
10-Q · filed 2022-11-14
$5.48M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$1.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$1.49M
10-Q · filed 2022-08-12
$2.09M
derived: sum of 3 quarters · filed 2022-08-12
$2.31M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31$387.00K
10-Q · filed 2022-05-13
$992.00K
derived: sum of 2 quarters · filed 2022-05-13
$1.20M
derived: sum of 3 quarters · filed 2022-05-13
-$1.44M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31$605.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
$817.00K
derived: sum of 2 quarters · filed 2022-03-11
-$1.83M
derived: sum of 3 quarters · filed 2022-03-11
-$2.60M
10-K · filed 2022-03-11
2020-09-30$212.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$2.44M
derived: sum of 2 quarters · filed 2021-11-12
-$3.21M
10-Q · filed 2021-11-12
2020-06-30-$2.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13
-$3.42M
10-Q · filed 2021-08-13
2020-03-31-$770.00K
10-Q · filed 2021-05-14
2019-09-30-$424.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
-$63.00K
derived: sum of 2 quarters · filed 2020-11-12
$717.00K
10-Q · filed 2020-11-12
$1.16M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$361.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
$1.14M
10-Q · filed 2020-08-13
$1.58M
derived: sum of 3 quarters · filed 2020-08-13
$1.47M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31$780.00K
10-Q · filed 2020-05-14
$1.22M
derived: sum of 2 quarters · filed 2020-05-14
$1.10M
derived: sum of 3 quarters · filed 2020-05-14
$1.57M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$439.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
$324.00K
derived: sum of 2 quarters · filed 2019-11-14
$787.00K
derived: sum of 3 quarters · filed 2019-11-14
$368.00K
10-K · filed 2019-04-01
2018-09-30-$115.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14
$348.00K
derived: sum of 2 quarters · filed 2019-11-14
-$71.00K
10-Q · filed 2019-11-14
-$113.00K
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30$463.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09
$44.00K
10-Q · filed 2019-08-09
$2.00K
derived: sum of 3 quarters · filed 2019-08-09
$1.61M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$419.00K
10-Q · filed 2019-05-15
-$461.00K
derived: sum of 2 quarters · filed 2019-05-15
$1.14M
derived: sum of 3 quarters · filed 2019-05-15
$911.00K
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$42.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
$1.56M
derived: sum of 2 quarters · filed 2019-04-01
$1.33M
derived: sum of 3 quarters · filed 2019-04-01
$1.09M
10-K · filed 2019-04-01
2017-09-30$1.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09
$1.37M
derived: sum of 2 quarters · filed 2018-11-09
$1.14M
10-Q · filed 2018-11-09
$2.04M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30-$232.00K
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2018-08-08
-$469.00K
10-Q · filed 2018-08-08
$435.00K
derived: sum of 3 quarters · filed 2018-08-08
$133.00K
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31-$237.00K
10-Q/A · filed 2018-08-08
$667.00K
derived: sum of 2 quarters · filed 2018-08-08
$365.00K
derived: sum of 3 quarters · filed 2018-08-08
$1.29M
derived: sum of 4 quarters · filed 2018-08-08
2016-12-31$904.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
$602.00K
derived: sum of 2 quarters · filed 2018-02-23
$1.53M
derived: sum of 3 quarters · filed 2018-02-23
$2.27M
10-K · filed 2018-02-23
2016-09-30-$302.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13
$623.00K
derived: sum of 2 quarters · filed 2017-11-13
$1.36M
10-Q · filed 2017-11-13
2016-06-30$925.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11
$1.67M
10-Q · filed 2017-08-11
2016-03-31$740.00K
10-Q · filed 2017-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06